PharmaEssentia Corporation Overview
Pro stress-test →PharmaEssentia is a global biopharmaceutical company developing best-in-class therapies for blood disorders and other serious diseases worldwide. Its lead product is Ropeginterferon alfa-2b (BESREMi®) for myeloproliferative neoplasms treatment, alongside pipeline candidates in T-cell receptor therapy, anti-PD-1 immunotherapies, and other novel biologics for solid tumors and hepatocellular carcinoma.
Strategic Profile
Pro stress-test →A fully integrated global biopharmaceutical company based in Taiwan that is competent in R&D, manufacturing, selling and marketing new drugs in the US. The company operates a world-class cGMP biologics facility in Taichung certified by the Taiwan FDA and compliant with US FDA and EMA requirements.
Competitive Landscape
Pro stress-test →PharmaEssentia competes in the myeloproliferative neoplasms treatment space with its differentiated Ropeginterferon alfa-2b product. Direct competitors in the orphan blood disorder and oncology immunotherapy markets include established pharma companies with interferon and checkpoint inhibitor portfolios, though PharmaEssentia's long-acting mono-pegylated formulation offers differentiation in dosing convenience.
Industry Context
PharmaEssentia Corporation operates in Biopharmaceutical Manufacturing & Development.
Key facts
Founded: 1990 · Headquarters: Taipei, Taiwan · Employees: 131 · Market cap: 242.3B TWD